-
2022-500014-26-00
5
2022-06-24
Locally-Advanced unresectable or Metastatic breast cancer (MBC)
-
2024-512378-91-00
4
2022-06-24
Unresectable or Advanced Melanoma
-
2023-507131-38-00
5
2022-05-16
Neovascular Age-Related Macular Degeneration (nAMD)
-
2023-504360-42-00
6
2022-05-13
Non-ST-segment elevation acute coronary syndrome
-
2023-504363-17-00
7
2022-05-13
Advanced MTAP-null solid tumors
-
2023-506359-68-00
5
2022-04-08
Active Proliferative Lupus Nephritis
-
2023-503868-16-00
5
2022-02-14
Small-Cell Lung Cancer (SCLC)
-
2023-505696-74-00
5
2022-02-10
systemic lupus erythematosus
-
2023-504884-17-00
5
2022-02-04
Proteinuria
-
2024-512163-31-00
10
2022-01-26
Amyotrophic Lateral Sclerosis with Fused in Sarcoma mutations
-
2023-509406-30-00
10
2022-01-24
Patients with HER2-overexpressing advanced or metastatic gastric or ga
-
2023-509631-37-00
5
2022-01-18
"Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Bre
-
2023-508242-18-00
6
2021-12-21
Crohn's disease
-
2024-511837-37-00
4
2021-12-21
Relapsed/Refractory Small Cell Lung Cancer
-
2023-503674-20-00
5
2021-12-17
Unresectable, locally advanced, or metastatic Non-Small Cell Lung Canc
-
2023-507974-42-00
4
2021-12-01
Moderate to Severe Ulcerative Colitis
-
2022-501067-40-00
5
2021-11-30
Moderately to Severely Active Ulcerative Colitis
-
2023-509133-39-00
5
2021-11-29
Hormone receptor positive, HER2-negative advanced breast cancer
-
2023-508248-23-00
5
2021-11-26
Non-alcoholic steatohepatitis (NASH)
-
2023-506518-33-00
5
2021-11-10
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
-
2023-506177-35-00
11
2021-10-23
Ovarian, fallopian tube, or primary peritoneal carcinoma.
-
2023-507130-24-00
5
2021-10-22
Neovascular age-related macular degeneration (nAMD)
-
2023-510319-20-00
5
2021-10-21
Gastroesophageal Adenocarcinoma (GEA)
-
2023-503441-55-00
4
2021-10-14
Relapsed/Refractory Multiple Myeloma